IPO registrations (S-1, F-1) · Registrants
BioNTech SE
- SEC CIK
- 1776985 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2019-09-09, last 2020-07-23; 4 initial registrations, 5 amendments
- Outcome
- Final prospectus filed 2019-10-11; declared effective 2019-10-09; withdrawal requested 2020-02-07
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- 2M
- Business address
- AN DER GOLDGRUBE 12, Mainz, 2M 55131
- Ticker
- BNTX (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- BioNTech SE on the corporate pages
Offering terms
- Proposed price range
- $15.00–$16.00 per ADS (F-1/A filed 2019-10-09)
- Final price
- $15.00 per ADS, within the range (424B4 filed 2019-10-11, an initial public offering)
- Shares sold
- 10,000,000
- Gross proceeds
- $150,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol BNTX
- Lead underwriters
- J.P. Morgan; BofA Securities; UBS; Leerink Partners
- Syndicate
- Canaccord Genuity; Bryan, Garnier & Co; Wolfe Research; Mirae Asset Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: BioNTech SE EXACT (CIK (EXACT))
- SEC filer: BioNTech SE EXACT (CIK (EXACT))
Filings 17
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-09-09 | F-1 | F-1 (foreign registration) | BioNTech SE | 0001193125-19-241112 ↗ |
| 2019-09-24 | F-1/A | F-1/A (amendment) | BioNTech SE | 0001193125-19-252726 ↗ |
| 2019-10-04 | F-1/A | F-1/A (amendment) | BioNTech SE | 0001193125-19-262865 ↗ |
| 2019-10-09 | F-1/A | F-1/A (amendment) | BioNTech SE | 0001193125-19-264798 ↗ |
| 2019-10-09 | EFFECT | EFFECT (declared effective) | BioNTech SE | 9999999995-19-002281 ↗ |
| 2019-10-11 | 424B4 | 424B4 (final prospectus) | BioNTech SE | 0001193125-19-266733 ↗ |
| 2020-02-03 | F-1 | F-1 (foreign registration) | BioNTech SE | 0001193125-20-022991 ↗ |
| 2020-02-05 | EFFECT | EFFECT (declared effective) | BioNTech SE | 9999999995-20-000265 ↗ |
| 2020-02-07 | RW | RW (withdrawal request) | BioNTech SE | 0001193125-20-028130 ↗ |
| 2020-04-02 | EFFECT | EFFECT (declared effective) | BioNTech SE | 9999999995-20-000676 ↗ |
| 2020-07-21 | F-1 | F-1 (foreign registration) | BioNTech SE | 0001193125-20-195911 ↗ |
| 2020-07-21 | F-1 | F-1 (foreign registration) | BioNTech SE | 0001193125-20-195916 ↗ |
| 2020-07-22 | F-1/A | F-1/A (amendment) | BioNTech SE | 0001193125-20-196813 ↗ |
| 2020-07-22 | F-1MEF | F-1MEF (added securities) | BioNTech SE | 0001193125-20-197246 ↗ |
| 2020-07-22 | EFFECT | EFFECT (declared effective) | BioNTech SE | 9999999995-20-001891 ↗ |
| 2020-07-23 | F-1/A | F-1/A (amendment) | BioNTech SE | 0001193125-20-197867 ↗ |
| 2020-07-24 | EFFECT | EFFECT (declared effective) | BioNTech SE | 9999999995-20-001920 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019-10-09 | F-1/A | registration statement | $15.00–$16.00 | 10,000,000 | - | Nasdaq BNTX | 8 | primary document; range, shares headline, cover names 8 | document ↗ | |
| 2019-10-11 | 424B4 | final prospectus | $15.00 | 10,000,000 | $150,000,000 | Nasdaq BNTX | 8 | primary document; price sentence, shares headline, proceeds table, cover names 8 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Hanekamp Annemarie | Officer | Chief Commercial Officer | 2 | 2026 | |
| Jeggle Helmut Wolfgang | Director | 1 | 2026 | ||
| Motschmann Michael | Director | 1 | 2026 | ||
| Poetting Sierk | Officer | Chief Operating Officer | 3 | 2026 | |
| Tureci Ozlem | Officer | Chief Medical Officer | 1 | 2026 | |
| Wandschneider Ulrich | Director | 1 | 2026 | ||
| Blackwood Nicola Claire | Director | 1 | 2026 | ||
| Jimenez Kylie | Officer | Chief People Officer | 2 | 2026 | |
| Morawietz Anja | Director | 1 | 2026 | ||
| Ryan James Timothy Patrick | Officer | See remarks. | 2 | 2026 | |
| Sahin Ugur | Officer,TenPercentOwner | Chief Executive Officer | 12 | 2026 | |
| Staudigl Rudolf | Director | 1 | 2026 | ||
| Zapata Gomez Ramon | Officer | Chief Financial Officer | 2 | 2026 | |
| Low-Friedrich Iris Katharina | Director | 1 | 2026 | ||
| Schaffert Susanne | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2022-04-14 | BioNTech SE | Biotechnology | $149,999,985 | $149,999,985 | 1 | 1 |
| 2020-09-17 | BioNTech SE | Biotechnology | $250,000,000 | $250,000,000 | 2 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | BioNTech SE | Form D private offerings | CIK (EXACT) | |
| SEC filer | BioNTech SE | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), 2M first:
- Immatics N.V. 2M
- CHEMOKINE THERAPEUTICS CORP A1
- Fusion Pharmaceuticals Inc. A6
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. AZ
- GENETIC TECHNOLOGIES LTD C3
- MESOBLAST LTD C3
- Ablynx NV C9
- SANGAMO THERAPEUTICS, INC CA
- GENITOPE CORP CA
- ABGENIX INC CA
In other datasets, the same topic (Health) in 2M:
- Form D issuer: ATAI Life Sciences AG (Form D private offerings)
Interests: Biological Products, (No Diagnostic Substances) · Health